What’s Next? Five Things To Look Out For In July
Teva Opioids Trial In San Francisco To Close; More Vasostrict ANDAs Anticipated
Executive Summary
This month, long-awaited new pricing measures in Canada will come into force, while several trials will either kick off or end, including a liability opioids case involving Teva in San Francisco and Hatch-Waxman litigation over Otsuka/Lundbeck’s Rexulti.
You may also be interested in...
Samsung Bioepis Goes After Lucentis With 40% Cheaper Byooviz Launch In US
Samsung Bioepis and Biogen have come in with a hefty discount as they mark a major milestone by launching their Byooviz biosimilar ranibizumab rival to Lucentis in the US.
Teva Inks $100m+ Deal To Settle West Virginia Opioid Claims
Teva has struck a further cash-and-medicines settlement agreement to resolve opioid-related claims in the US. A bench trial had been due to start in West Virginia by the end of this month, where Teva is to pay $75m over 15 years plus generic Narcan.
Goldman Ends Endo Coverage Following Q2 EBITDA Guide
One of the largest investment banks in the US has cancelled its coverage of Endo after the US-based firm revealed the extent of generic competition to its lucrative Vasostrict brand.